Phenoxypropazine

● Article ● Talk ● Language ● Watch ● Edit

Phenoxypropazine (trade name Drazine) is an irreversible and non-selective monoamine oxidase inhibitor (MAOI) of the hydrazine family. It was introduced as an antidepressant in 1961, but was subsequently withdrawn in 1966 due to hepatotoxicity concerns.^[1]^[2]^[3]^[4]^[5]

Phenoxypropazine
Clinical data

Routes of administration	Oral
ATC code	none
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name (1-methyl-2-phenoxy-ethyl)hydrazine
CAS Number	3818-37-9
PubChem CID	71467
ChemSpider	64548
UNII	8E92V52324
ChEMBL	ChEMBL1909286
CompTox Dashboard (EPA)	DTXSID1048837
Chemical and physical data
Formula	C₉H₁₄N₂O
Molar mass	166.224 g·mol⁻¹

References

^ LEAHY MR, ROSE JT, PLOWMAN R (April 1963). "A preliminary study of phenoxypropazine in the treatment of depression". The American Journal of Psychiatry. 119 (10): 986–7. doi:10.1176/ajp.119.10.986. PMID 13928824.

^ IMLAH NW (May 1963). "Preliminary report on phenoxypropazine". The American Journal of Psychiatry. 119 (11): 1091–2. doi:10.1176/ajp.119.11.1091. PMID 13956423.

^ ROSE JT, LEAHY MR, PLOWMAN R (October 1963). "A comparison of phenoxypropazine and amitriptyline in depression". The American Journal of Psychiatry. 120 (4): 393–5. doi:10.1176/ajp.120.4.393. PMID 14069469.

^ ROSE JT (March 1964). "Phenoxypropazine and chlordiazepoxide in depression". The American Journal of Psychiatry. 120 (9): 899–900. doi:10.1176/ajp.120.9.899. PMID 14129290.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Phenoxypropazine&oldid=1144171123" Last edited on 12 March 2023, at 05:48

●This page was last edited on 12 March 2023, at 05:48 (UTC). ●Content is available under CC BY-SA 4.0 unless otherwise noted. ●Privacy policy ●About Wikipedia ●Disclaimers ●Contact Wikipedia ●Code of Conduct ●Developers ●Statistics ●Cookie statement ●Terms of Use ●Desktop